Recurrent dvt chest guidelines

The American Society of Hematology (ASH) has developed new guidelines for the management of venous thromboembolism (VTE). The guidelines contain 10 chapters that focus on current areas of uncertainty and changes in clinical practice in the management of deep vein thrombosis and pulmonary embolism. To develop the new guidelines, ASH, in partnership with MCMaster University, has created a multidisciplinary team that has used the GRADE (Recommendation, Development and Evaluation Assessment) approach to evaluate evidence and make recommendations. 10 Chapter 1) VTE Diagnosis; 2) prevention of VTE in hospitalized patients; 3) optimal management of anticoagulants; 4) heparin-induced thrombocytopenia; 5) Children's VTE; 6) VTE in the context of pregnancy; 7) prevention of VTE in surgically hospitalized patients; 8) prevention and treatment of VTE in cancer patients; 9) Thrombophilia; and 10) treatment of acute VTE. The six chapters that have been released so far, all available on the ASH website, contain 149 recommendations. Key differences between the two guidelines include the fact that chest guidelines are now 6 years old and do not contain much information about the use of DOACs (direct action anticoagulants) in clinical practice, said Daniel M. Witt, PharmD, FCCP, BCPS. Witt, of the University of Utah Pharmacy College, is the lead author of a new chapter on optimization of anticoagulation therapy. Clinics should compare the new ASH guidelines with CHEST ones to better understand their similarities and differences. There were many issues in the ASH guidelines that were not addressed in the CHEST guidelines and vice versa, so the two guidelines should probably be used together by pharmacists rather than one to replace the other, Witt said. Pharmacists should also be aware of the similarities and differences between ash guidelines and anticoagulation guidelines issued in 2012 by the American College of Chest Physicians. For the full article, please visit www.pharmacytoday.org for the February 2019 Pharmacy issue today. Updated COVID-19 Management Guidelines: The International Task Force (July 29, 2020) was coordinated from the American Thoracic Society/European Respiratory Society. Bai C, Chotirmall SH, Rello J, Alba GA, Ginns LC, Krishnan JA, Rogers R, Bendstrup E, Burgel PR, Chalmers JD, Chua, Crothers CA, Duggal A,

Kim YW, Laffy JG, Luna CM, Niederman MS, Ragu G, Ramirez JA, Ryer, J Rock Chen R, Cortez-Puentes GA, Delacruz C, Hayes MM, Heunks LMA, Holets SR, Hough CL, Jagpal S, Jeon K, Johkoh T, Lee MM, Liebler J, Mc Elvaney GN, Moskowitz A, Oeckler RA, Ojanguren I, O'Regan, X, Wuyts W, Xu T, Yang D, Chang Tzu, Wilson KC. Bai C, et al. Eur Respir Rev. 2020 Oct 5;29 (157):200287. doi: 10.1183/16000617.0287-2020. Print2020 on September 30. Eur Respir Rev. 2020. PMID: 33020069 Free PMC article. Reviews. 1. Ju T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for relapse. Atherosclerosis Thromb Vask Biol. 2009;29(3):298-310....2. Prandoni P, Lensing AW, Kogo A, et al Long-term Clinical Course of Acute Deep Venous Thrombosis. Anne Intern Med. 1996;125(1):1-7.3. Christiansen SC, Cannegieter SC, Bonfire T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurring venous thrombotic events. Jama. 2005;293(19):2352–2361.4. Kieron C, Kahn SR, Agnelli G, Goldhaber S, Rascob GE, Comerota AJ. Antithrombotic Therapy for Venous Thromboembolic Diseases: American College of Chest Physicians based on evidence from clinical practice guidelines (8th edition) published correction appears in the breast. 2008;134(4):892. Breast. 2008;133(6 suppl):454S-545S.5. Chait Y, Condat B, Cazals-Hatem D, et al. Actuality criteria commonly used for diagnosis of myeloproliferative disorder in patients with planned vein thrombosis. Br J Haematol. 2005;129(4):553–560.6. Mahmoodi B.C., ten Kate MK, Waanders F, etc. High absolute risks and predictors of venous and arterial thromboembolic phenomena in patients with nephrotic syndrome: results of a large retrospective cohort study. Circulation. 2008;117(2):224–230.7. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsch J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians based on evidence-based clinical practice guidelines (8th edition). Breast. 2008;133(6 suppl):844S-886S.8. Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk of venous thromboembolism. Anne Intern Med. 2009;151(3):180-190.9. Kearon C. Long-term management of patients after venous thromboembolism. Circulation. 2004;110(9 suppl 1):I10-I18.10. Pernod G, Byron-Andreani C, Morange PE, French group on hemostasis and thrombosis; French Society of Vascular Medicine, et al. Recommendations for testing for thrombophilia for venous thromboembolic disease: a French guide to consensus. J.M. Vask. 2009;34(3):156–203.11. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523–526.12. Ho WK, Hanky GJ, quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with general thrombophilia: a systematic review. Arch Intern Med. 2006;166(7):729-736.13. Garcia D. Duration of anticoagulant therapy for patients with venous thromboembolism. Clot 2008;123 (suppl 1):S62-S64.14. Prandoni, NoventA F, Girarduzzi A. et al. Risk of recurrent venous thromboembolism after termination in patients with acute proximal deep vein thrombosis or pulmonary embolism. Prospective cohort study in 1,626 patients. Hematology. 2007;92(2):199–205.15. Shulman S, Rhedin AS, Lindmarker P, et al. Comparison of six weeks with six months of oral anticoagulant therapy after the first episode of venous thromboembolism. The duration of the anticoagulation trial group. N Engl J Med. 1995;332(25):1661-1665.16. Hansson PO, Serbo J, Eriksson H. Recurring venous thromboembolism after deep vein thrombosis: frequency and risk factors. Arch Intern Med. 2000;160(6):769-774.17. Martinelli I, Mannucci PM, De Stefano V, et al. Various risks of thrombosis in four coagulation defects associated with hereditary thrombophilia: a study of 150 families. Blood. 1998;92(7):2353–2358.18. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. The ratio of anti beta2-glycoprotein I and antiprothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Hemost's clot. 1997;78(3):1008–1014.19. Segal JB, Brotman DJ, Emadi A, et al. Results of genetic testing in adults with a history of venous thromboembolism. David Rep Technol Score (Full Rep). 2009(180):1–162.20. Con D, Vansenne F, de Borgie C, Middeldorp S. Thrombophilia testing to prevent recurrent venous thromboembolism. Cochrane database Syst Rev. 2009; (1):CD007069.21. Simpson EL, Stevenson MD, Rawdin A, Papaioannou D. Thrombophilia testing in people with venous thromboembolism: a systematic review and cost effectiveness analysis. Health Technol Assessment. 2009;13(2):1–91.22. Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schenemann HJ. Grade recommendations for antithrombotic agents: American College of Chest Physicians based on evidence of clinical practice guidelines (8th edition) published correction appears in the breast. 2008;134(2):473. Breast. 2008;133(6 suppl):123S-131S.23. Hirsch J, Guyatt G, Albers GW, Harrington R, Schnemann HJ. Summary: American College of Chest Physicians based on evidence of clinical practice guidelines (8th edition) published correction appears in the breast. 2008;134(4):892. Breast. 2008;133(6 suppl):71S-109S.24. Baglin T, Barrowcliff TW, Cohen A, Greaves M; British Committee on Standards in Hematology. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006;133(1):19–34.25. Mall S, Ortel TL. Monitoring of warfarin therapy in patients with lupus anticoagulants. Anne Intern Med. 1997;127 (3):177-185.26. Kato S, Chernyavsky S, Tokita JE, et al. Link between proteinuria and venous thromboembolism published on the eve of printing on February 16, 2010. Thrombolysis J Thrombolysis. (subscription required). Access September 21, 2010.27. McBane RD II, Highinsky ME. Treatment of venous thrombosis in Places. Curr Treat Options Cardiovasc Med. Med. Chan MY, Becker RC. Identification and treatment of arterial thrombophilia. Curr Treat Options Cardiovasc Med. 2008;10(1):3-11.29. Verkhovsek M, Duketis J.D., I.S. et al. Systematic review: d-dimer for predicting recurrent diseases after the termination of anticoagulant therapy of unprovoked venous thromboembolism. Anne Intern Med. 2008;149(7):481-490W94.30. Prandoni P, Objecting AW, Prince MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Anne Intern Med. 2002;137(12):955-960.31. Cosmi B., Leknini C, Iorio A, et al.; PROLONG investigators. Residual venous obstruction, alone and in combination with d-dimer, is a risk factor for relapse after the withdrawal of anticoagulation after the first idiopathic deep vein thrombosis in the extended study. Eur J Vask Endovask Surgut. 2010;39(3):356-365.32. Mia S., Lokshyn MD, Atsumi T, et al. International Consensus Statement on updating classification criteria for a certain antiphospholipid syndrome (APS). J Tromb Hemost. 2006;4(2):295–306.33. Piccioli A, Lensing AW, Prins MH et al; SOMIT's team of investigators. Extensive screening for occult malignancies in idiopathic venous thromboembolism: a promising randomized clinical trial. J Tromb Hemost. 2004;2(6):884–889.34. Sorensen HT, Melemkjaer L, Olsen JH, Baron JA. Prognosis of cancer associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850.35. Paneesha S, McManus A, Arya R, et al; VERITY INVESTIGATORS. Frequency, demographics and risk (depending on the type of tumor or site) of cancer-related thrombosis among patients seen in DVT outpatient clinics. Hemost's clot. 2010;103(2):338–343.36. Montreal M, Lensing AW, Prince MH, et al Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Tromb Hemost. 2004;2(6):876–881.37. Trujillo-Santos J, Prandoni P, Rivron-Guillot K, et al.; RIETE Investigators. Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE registry. J Tromb Hemost. 2008;6(2):251–255.38. Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Roger M.A. Systematic review: Trusso syndrome again: should we screen widely for cancer in patients with venous thromboembolism? Anne Intern Med. 2008;149(5):323-333.39. Lee AY, Levin MN, Baker RI, et al; Randomized comparison of low molecular-weight heparin vs. oral anticoagulant therapy to prevent recurrent venous thromboembolism in cancer patients (CLOT) researchers. Heparin with low molecular weight against coumarin to prevent recurrent venous thromboembolism in cancer patients. N Engl J Med. 2003;349(2):146-153.40. Snow V, Kasim A., Barry. et al. Management of venous thromboembolism: a guide to clinical practice of the American College of Physicians and the American Academy Doctors published correction appears in Ann Fam Med. 2007;5(2):179». Ann Fam Med. 2007;5(1):74-80.Page 2PATRICK E. McCLESKEY, MAJ, USAF, MC, and JAMES SARASUA, CAPT, USAF, MC, David Grant Medical Center, Travis Air Force Base, CaliforniaAm Fam Physician. 2011 February 1;83(3):307-308.A 66-year-old male is presented with a red, scaly, slightly itchy skin rash that persisted for five years. It began on the left big note and advanced to his feet and inner hands. The rash does not respond to topical or systemic terbinafin (Lamisil) or itraconazole (Sporanox). Otherwise he was healthy without constitutional symptoms, and has not started any new medication recently. Physical examination revealed large ring, erythemacal areas with central cleaning and internal scaling ring. Defeats were present on the left inner arm (Figure 1) and the left medial hip (Figure 2). Two small patches were present on the left buttock and right back thigh. The soles, palms and nails were not damaged. The findings of potassium hydroxide (KOH) skin drugs were negative. Skin biopsy revealed epidermal spongy effect, superficial perivascular lymphocytic infiltration without epidermotropy, as well as negative conclusions about periodic acid-schiff spots. Based on patient history and physical examination, one of the following is the most likely diagnosis?A. Erythema annulare centrifugum.B. Granuloma annulare.C. Mycosis fungoides.D. Pityriasis rosea.E. Tinea corporis. Answer A: erythema annulare centrifuge. Patients with erythema annulare centrifuges are classically present with erythemamatous, ring-shaped or archabutate (curved) spots on the trunk or proximal limbs. Defeats expand with central cleaning, and scaling is present on the back edge of the erythema. The disorder is often itchy and usually spares the palms, soles and mucous membrane. Patients with erythema annulare centrifuges have negative findings about THE drugs, and the condition usually does not respond to antifungal therapy.1Erythema annulare centrifuge is commonly associated with epidermal spongy and superficial perivascular lymphocytic infiltration. Histology is relatively non-specific. A biopsy may exclude other diagnoses such as tinea corporis, subacute skin lupus erythematosus, or mycosis fungoides.1 Erythema annulare centrifugum may have a histological reaction pattern suggestive of thumid lupus; spongy dermatitis; or pseudolimpoma, which has been associated with borrelia species in Europe.2 Erythema annulare centrifugum, usually idiopathic.1 Treatment with powerful topical steroids is the basis of therapy, but calcipototriol (called calcipotite Dovonex in the United States)3 and metronidazole (Metrogel)4 have also been used. Granuloma annulare presents as non-cracking, ring-shaped or archatuat, double-learning plaques.5 Plaques are commonly found on limbs, limbs, or in groups. Mycosis fungoides often presents both erythematous spots or plaques on the trunk or sun-protected skin, but usually lacks central cleaning. Defeats often persist for years. Pityriasis Rose begins with a heraldic patch that may appear as an erythema ring lesion, but subsequent patches develop into a symmetrical Christmas tree pattern.5 Patients with the condition often have a wide truncal distribution of oval, salmon-colored patches with collarettes scaling. Pityriasis rosea is more common in patients younger than 35 years of age and occurs along the skin tension lines on the central trunk. This usually decides within a few months. Tinea corporis is much more common than erythema annulare centrifuges. The condition leads to erythetic, ring-shaped spots on the trunk or limbs. Scaling takes place at the forefront of defeats, as opposed to the back edge with erythema annulare centrifuges. The drug KOH or fungal culture must be performed to confirm a dermatophic infection. Extensive tinea corporis may require oral terbinafine.5 When suspected dermatophitis infections do not respond to standard treatments, alternative diagnoses should be considered. A skin biopsy may be required to rule out other conditions. To see the full article, log in or buy access. Address correspondence Patrick E. McCleskey, MAJ, U.S. Air Force, MC, patrick.mccleskey@us.af.mil. Reprints are not available to authors. Author Disclosure: Nothing to disclose. The opinions and statements contained in this present are the authors' private views and should not be construed as official or reflective of the views of the U.S. Air Force Medical Department or the U.S. Air Force on large.show all references1. Espana A. Figurative erythema. In: Bologna JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2d ed. St. Louis, Mo.: Mosby; 2008:277–281....2. Sieter M., Eisendl K., Selger B. New concepts of erythema centrifuge annulare: a clinical model of reaction that does not represent a specific clinical pathological entity. Br J Dermatol. 2009;160(1):119–126.3. Gniadecki R. Calcipotriol for erythema annulare centrifuge. Br J Dermatol. 2002;146(2):317–319.4. De Aloe G, Rubegni P, Risulo M, Sbano P, Poggiali S, Fimiani M. Erythemaular anne centrifugum successfully treated with metronidazole. Wedge Ext Dermatol. 2005;30(5):583–584.5. Hsu S, Le EH, Khoshevis MR. Differential diagnosis of ring-shaped lesions. Am Pham Doctor. 2001;64(2):289-296.Contribution by photo quiz editor John E. Delzell Jr., MD, MSPH. A collection of photo quizzes published by AFP is available on . AFP editors welcome the materials for the photo quiz. Guidelines for the preparation and dispatch of the Photovisation manuscript can be found in the authors' Guide to . In order to be to publish, submissions must comply with these Emailing afpphoto@aafp.org. Page 3 Practitioner GuidelinesIt is a corrected version of the practice guidelines that have appeared in the press. DOUG CAMPOS-OUTCALT, MD, MPA, University of Arizona College of Medicine, Phoenix, ArizonaAm Pham Doctor. 2011 February 1;83(3):318-322.Download Child and Adolescent Immunization Schedules.Download Adult Immunization Schedule.Each year The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention updates recommended immunization schedules for children, adolescents and adults. These graphs describe the immunization recommendations recommended for regular introduction in each age group and contain changes and new recommendations adopted by asSIP for the previous 12 months. There are only a few new recommendations in this year's schedules, most notably the universal introduction of the flu vaccine for all people six months and older, and the replacement of the 7-valent pneumococcal conjugation vaccine (Prevnar) with a 13-valent product (Prevnar 13) for infants and children.1.2ACIP has included several other changes to the schedule, although they have not yet been published. These changes include: administering a quadrivalent meningococcal conjugation vaccine (MCV4) in a two-dose primary series, rather than a single dose, for children at high risk of immunocompromatical conditions. Administer the booster dose of MCV4 at age 16 for individuals who have been vaccinated between the ages of 11 and 12, or four to five years old after the first dose for those vaccinated between the ages of 13 and 15. Administration tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) for adults 65 years and older who are in close contact with infants. It's a recommendation that's not made. The Administration of Tdap for children from seven to 10 years old who have not completed a series of diphtheria and tetanus toxoid and whooping cough vaccine (DTaP). It's a recommendation that's not made. Eliminating the recommended interval between tetanus and the toxoid diphtheria vaccine (Td) and Tdap.There are several explanations in this year's footnote schedules, including an explanation for the interval of the three-dose primary series of hepatitis B vaccine (Gepb) for infants who did not receive the dose immediately Birth timeline of the third HepB HepB situations in which children under the age of nine require two doses of influenza vaccine; the presence of two vaccines against human papillomavirus to prevent cervical cancer (quadrivalent and bivalent)3; and the presence of a quadrivalent vaccine against the human papillomavirus to prevent genital warts in men. Over time, vaccines have become one of the most effective public health interventions. Many modern physicians have never seen a patient with measles, rubella, polio or other diseases that in the past were the leading causes of morbidity and mortality. It can be said that vaccines are a victim of their own success, the better they work, the less they are valued. In the absence of vaccine-preventable diseases, the benefits of vaccines go unnoticed, while exaggerated and false claims about harm are receiving increasing attention, and safety concerns are becoming the most important issue for parents. Family doctors now have to spend more time assuring patients and families of the safety and efficacy of vaccines. As more vaccines are licensed and protection against more infectious diseases becomes available, the growing complexity of vaccination schedules is a challenge for family doctors, as is the logistics of maintaining a full range of vaccines in a clinical setting.4 I hope family doctors will find creative ways to continue to provide vaccines in the medical home. If not, others step in to provide this effective and important service. Page 4 Please note: This information was current at the time of publication. But medical information is constantly changing, and some of the information presented here may be out of date. For regular updates on various health issues, please visit familydoctor.org, AAFP Patient Education website. Am Pham Doctor. 2011 Feb 1;83(3):303-304. See relevant articles about venous thromboembolism. Venous thromboembolism, or VTE, occurs when a blood clot is formed in a large vein deep in your body. This clot is called deep venous thrombosis. It usually occurs in the leg, causing pain, swelling, and redness. If a blood clot forms in the lungs, or if part of the blood clot in the leg breaks out and goes to the lungs, it is called a pulmonary embolism. Your doctor can give you medication to treat a blood clot. The medicine helps stop the clot from getting bigger and keeps new clots from forming. The clot will disappear on its own in three to six months. A large blood clot in the lungs can be fatal. A blood clot can also damage the veins in the legs. Symptoms of vein damage include pain, veins that are more noticeable than usual, changes in skin color, and swelling of the legs. Medications that treat blood clots may increase the likelihood Problems. Most people still need to take their medicine. Your doctor can help you prevent bleeding and decide how long you should take to take The doctor will check your blood and adjust how many medications you are taking. Other medications that you take and what you eat can affect your treatment. For example, vitamin K, which is found in many green leafy vegetables, may make treatment less effective. Your doctor can tell you what to avoid. Here's to help prevent blood clots from forming: Avoid long periods of inactivity during long journeys, during illness, or after surgery. Walk every two hours. Exercise your feet, sitting, lifting and lowering your legs, and then repeating with your heels. If you smoke, you should quit smoking because it damages blood vessels and may increase the risk of blood clots. Tell your doctor if you have a blood clot before you start a new medication. Some medications, like birth control pills or hormones, may increase the risk of a blood clot. If you have had a blood clot caused by a recent operation, hospitalization, trauma, wearing plaster, long trips, pregnancy or certain medications, you are unlikely to get another blood clot. If no cause has been found for your blood clot, you may have a higher risk of getting another one. You should talk to your doctor about your risk of having repeated blood clots. To see the full article, log in or buy access. This handout is provided to you by your family doctor and the American Academy of Family Physicians. Other health-related information is available online in AAFP . This information provides a general overview and may not apply to everyone. Talk to your family doctor to find out if this information applies to you and get more information on the subject. chest guidelines recurrent dvt